Phase III trial update of P2B001 for Parkinson's disease

Phase III trial update of P2B001 for Parkinson's diseaseПодробнее

P2B001: a slow-release drug for Parkinson’s diseaseПодробнее

Update on Parkinson’s disease clinical trialsПодробнее

Pivotal Phase III BouNDless Trial for Parkinson’s Disease Patients with Motor FluctuationsПодробнее

GRBJ—VAI partners with Cure Parkinson’s in clinical drug trialПодробнее

Learnings from clinical trial failure in Parkinson's diseaseПодробнее

Professor Tom Foltynie - The Bydureon: phase 3 trialПодробнее

The ASPro PD phase 3 clinical trial of Ambroxol by Cure Parkinson's.An update and panel discussionПодробнее

Phase III trial of phototherapy in Parkinson's diseaseПодробнее

BioVie releases phase 2 trial results for Parkinson's Disease treatmentПодробнее

Clinical Trial: Tavapadon for Parkinson's Disease (NCT04223193)Подробнее

Do GDNF clinical trial results offer hope for Parkinson's?Подробнее

Phase III SPARX3 trial of moderate- vs. high-intensity exercise to slow progression in PDПодробнее

Parkinson's Disease and Clinical TrialsПодробнее

PADOVA trial: prasinezumab in early Parkinson's diseaseПодробнее

TRAP: Symptoms of Parkinson Disease | Medical Mnemonic | Merck Manual Professional VersionПодробнее

What have clinical trials taught us about Parkinson's disease?Подробнее

P2B001 Research StudyПодробнее

New Parkinson Disease Clinical Trial: Citalopram 20mg for Parkinson DiseaseПодробнее

Moving Forward: Clinical Trials in Parkinson's DiseaseПодробнее